Compare · CNC vs DNAY
CNC vs DNAY
Side-by-side comparison of Centene Corporation (CNC) and Codex DNA Inc. (DNAY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and DNAY operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $31.31B, about 146.4x DNAY ($213.9M).
- CNC has hit the wire 3 times in the past 4 weeks while DNAY has been quiet.
- CNC has more recent analyst coverage (25 ratings vs 5 for DNAY).
- Company
- Centene Corporation
- Codex DNA Inc.
- Price
- $63.40-0.51%
- $1.20-4.76%
- Market cap
- $31.31B
- $213.9M
- 1M return
- +0.69%
- -
- 1Y return
- +136.02%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 5
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Codex DNA Inc.
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Latest CNC
- Director Tyler Lauren M was granted 3,155 shares, increasing direct ownership by 5,172% to 3,216 units (SEC Form 4)
- CENTENE CORPORATION TO HOST 2026 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL
- CENTENE SUBSIDIARY MERIDIAN HEALTH PLAN OF ILLINOIS AWARDED ILLINOIS MEDICAID CONTRACT
- Director Tyler Lauren M was granted 61 shares (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 465 shares, increasing direct ownership by 2% to 25,213 units (SEC Form 4)
- Director Tanji Kenneth was granted 581 shares, increasing direct ownership by 5% to 12,490 units (SEC Form 4)
- Director Eppinger Frederick H was granted 833 shares, increasing direct ownership by 0.23% to 369,538 units (SEC Form 4)
- Director Coughlin Christopher J was granted 562 shares, increasing direct ownership by 3% to 18,711 units (SEC Form 4)
- Health Net Providing Special Assistance to Members and Providers Affected by Palos Warehouse Fire in Los Angeles
- RBC Capital Mkts initiated coverage on Centene with a new price target
Latest DNAY
- SEC Form 4 filed by Kullback William J
- SEC Form 3 filed by new insider Kullback William J
- Codex DNA Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by Codex DNA Inc.
- Codex DNA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Codex DNA Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation
- Herrema Gregory J. was granted 153,191 shares (SEC Form 4)
- SEC Form 3 filed by new insider Herrema Gregory J.
- Codex DNA Inc. filed SEC Form 8-K: Leadership Update
- Codex DNA Inc. filed SEC Form 8-K: Leadership Update